missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human PMSCL1 (aa 122-197) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (99%), Rat (99%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-59749 (PA5-59749. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a component of the human exosome, a exoribonuclease complex which processes and degrades RNA in the nucleus and cytoplasm. This component may play a role in mRNA degradation and the polymyositis/scleroderma autoantigen complex. Alternative splicing results in multiple transcript variants.
Specifications
Specifications
| Accession Number | Q06265 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 5393 |
| Name | Human PMSCL1 (aa 122-197) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | autoantigen PM/Scl 1; EXOSC9; Exosome complex component RRP45; exosome complex exonuclease RRP45; exosome component 9; exosome component; PM/Scl - 75; p5; p6; P75 polymyositis-scleroderma overlap syndrome associated autoantigen; P75 polymyositis-scleroderma overlap syndrome-associated autoantigen; PM/Scl-75; PMSCL autoantigen, 75 kD; PMSCL1; Polymyositis/scleroderma autoantigen 1; polymyositis/scleroderma autoantigen 1, 75 kDa; polymyositis/scleroderma autoantigen 75 kDa; RRP45; Rrp45p |
| Common Name | PMSCL1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction